HUMAHealthcare · BiotechnologyThe 6 Wall Street analysts covering Humacyte, Inc. hold a median 12-month price target of $1.13 — +151.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Humacyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (73): Smaller than most of the companies we track.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HUMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +151.6% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | Benchmark | Maintains | Speculative Buy | $2.00 → $1.00 |
| 28 July 2026 | BTIG | Reiterates | Buy | $2.00 |
| 28 July 2026 | BTIG | Reiterates | Buy | — |
| 17 June 2026 | TD Cowen | Maintains | Buy | — |
| 17 June 2026 | TD Cowen | Maintains | Buy | $1.50 → $1.25 |
| 16 June 2026 | BTIG | Reiterates | Buy | — |
| 16 June 2026 | BTIG | Reiterates | Buy | $2.00 |
| 11 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 June 2026 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $4.00 |
| 8 June 2026 | BTIG | Reiterates | Buy | — |
| 1 June 2026 | Benchmark | Maintains | Speculative Buy | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | TD Cowen | Maintains | Buy | — |
| 13 May 2026 | BTIG | Maintains | Buy | — |
| 28 Apr 2026 | BTIG | Reiterates | Buy | — |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 24 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Apr 2026 | Barclays | Maintains | Overweight | — |
| 31 Mar 2026 | Benchmark | Downgrade | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HUMA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Humacyte, Inc. returned −73.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 5% of US stocks
Cheaper than 24% of US stocks
Cheaper than 69% of US stocks
Higher than 80% of US stocks
Higher than 69% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Humacyte, Inc. has a market value of $131.2M and an enterprise value of $118.2M.
Revenue in the twelve months to 30 June 2026: $2.1M. The latest quarter grew 34.9% year on year.
Net income over the same four quarters: −$96.7M, a −4560.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$97.6M.
Trailing P/E: −1.8×; forward P/E: −1.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Humacyte, Inc. employs 184 people — $12K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Humacyte, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Humacyte, Inc. (HUMA) closed the recent trading session at $0.48, down 4.26% from the prior day's close.
Why it matters — The session's decline is a recent price move that HUMA watchers may want to note.
Humacyte, Inc. (HUMA) shares fell 2.86% to close at $0.5 in the recent trading session, a decline that occurred despite broader market gains. The stock's drop sets it apart from the prevailing market trend on that day.
Why it matters — A HUMA watcher would note the stock's underperformance relative to the broader market, as its decline contrasts with market gains.
Humacyte announced the appointment of Scott Coward and Paul Kuznik to its Board of Directors. Both are life science industry veterans with experience in commercialization, enterprise leadership, and global operations.
Why it matters — Adding directors with commercialization and enterprise leadership expertise strengthens the board's capabilities as Humacyte, a commercial-stage biotechnology company, continues scaling its business.
Humacyte, Inc. (HUMA) shares fell 2% on the latest trading day, closing at $0.56, a decline from the previous close even as the broader market gained.
Why it matters — HUMA watchers would note that the stock declined against a rising broader market, indicating underperformance in that session.
Humacyte, Inc. (HUMA) closed at $0.59 in the latest trading day, reflecting a +2.23% change compared to its previous close, outperforming the broader stock market upswing.
Why it matters — A HUMA watcher would care because the stock's positive move relative to the broader market indicates the company is gaining investor attention worth monitoring.
The 6 Wall Street analysts covering Humacyte, Inc. have a median 12-month price target of $1.13, with estimates ranging from $0.5 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Humacyte, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Humacyte, Inc. 18 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Humacyte, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +151.6% from the last close, and Ticker Nerd's factor model ranks Humacyte, Inc. 18 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Humacyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HUMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.5 to $4 over the next 12 months.
Humacyte, Inc. returned -73.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable.
The most recent item we track (Zacks Investment Research, 6 Oct 2026): "Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade". Humacyte, Inc. (HUMA) closed the recent trading session at $0.48, down 4.26% from the prior day's close.
Humacyte Inc. is a biotechnology company focused on developing and manufacturing off-the-shelf, bioengineered human tissues designed to be universally implantable. Its core platform centers on acellular tissue technologies, including human acellular vessels, that are intended to support vascular repair and reconstruction across multiple medical settings. The company’s products and programs address critical needs in areas such as vascular trauma, hemodialysis access, peripheral arterial disease, and other regenerative medicine applications. Humacyte also works on advanced tissue constructs and organ systems, positioning its technology at the intersection of regenerative medicine, bioengineering, and surgical care. Headquartered in Durham, North Carolina, Humacyte serves the healthcare market through its commercial-stage development and manufacturing capabilities.
CEO Dr. Laura E. Niklason M.D., Ph.D. · 184 employees · United States · https://www.humacyte.com
